Stock of BioTime Subsidiary to Begin Trading on the NYSE MKT

- December 30th, 2015

BioTime, Inc. (NYSE MKT:BTX) has reported that the common stock of subsidiary OncoCyte Corporation will start trading on a “when-issued” basis on the NYSE MKT under the symbol OCX WI.

BioTime, Inc. (NYSE MKT:BTX) has reported that the common stock of subsidiary OncoCyte Corporation will start trading on a “when-issued” basis on the NYSE MKT under the symbol OCX WI.
According to the press release:

“Regular-way” trading of OncoCyte common stock on the NYSE MKT is expected to begin on January 4, 2016 under the symbol OCX.
As previously announced, the Board of Directors of BioTime declared a pro rata distribution of shares of OncoCyte common stock to BioTime shareholders of record as of the close of business on December 21, 2015, the record date. As a result, on December 31, 2015, BioTime shareholders will receive one share of common stock of OncoCyte for every twenty BioTime common shares they held on the record date. Fractional shares of OncoCyte common stock will not be distributed to BioTime shareholders. Instead, the fractional shares of OncoCyte common stock will be aggregated and sold in the open market, with the net cash proceeds distributed pro rata to the BioTime shareholders who otherwise would have received fractional shares of OncoCyte common stock.
No action is required by BioTime shareholders to receive the distributed shares of OncoCyte common stock. BioTime shareholders who held BioTime common shares on the record date and do not sell those shares prior to December 31, 2015 will receive a book-entry account statement reflecting their ownership of OncoCyte common stock or their brokerage account will be credited with OncoCyte shares.

Click here to read the full press release.

Looking for great biotech companies?

 
Find new opportunities and valuable news in your free report
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

Leave a Reply

Your email address will not be published. Required fields are marked *